Advancing neuroprotection requires greater conceptual clarity, inclusivity, and technological innovation to overcome current barriers
KPV enters cells via a transporter that is upregulated in inflamed tissues, providing targeted delivery to areas of active inflammation
Rather than being a pharmaceutical development, this tripeptide occurs naturally in human blood plasma, with concentrations around 200 ng/mL at age 20 that decline to approximately 80 ng/mL by age 60
Furthermore, the systemic neuroinflammation driven by this oxidative stress directly impacts the autonomic nervous system
10.1626/pps.13.164 152 YeX
Following washing with PBS, the primary antibody, CD36 (5114-PE100T, 1:20 dilution, BioCytex), was added, and cells were incubated at 4 C overnight